Determining LIMS Functionality, Cost, and ROI: System Architecture Strengths and Limitations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Determining LIMS Functionality, Cost, and ROI: System Architecture Strengths and Limitations
Before any information technology solution can be installed, a company must decide whether applications are going to reside on individual computers at each employee's workstation, on servers within or outside of an organization, or on a vendor's website.


Pharmaceutical Technology


It may also be important to consider whether remote handheld devices are critical to the laboratory. If so, see whether the thick-client LIMS can run on a portable device and assess whether the necessary .NET support browser is available for PDAs and other handheld devices used in the laboratory. This can be a significant issue to organizations that conduct R&D in the field or perform activities such as environmental monitoring on the plant floor.

Summary

There are significant differences between thick-client, web-enabled, web-based, and thin-client solutions. Thick-clients are desktop client applications that connect to a remote database. Web-enabled solutions are more oriented toward thick or rich clients, and web-based solutions offer some of the benefits of thin-client applications. Thin-clients, on the other hand, are true HTML applications that do not require additional end-user client downloads, applets, or frameworks. Just be sure a firm knows what it's getting by being aware of the differences, advantages, and disadvantages of each type of solution in relation to its existing or planned infrastructure. Many organizations are choosing thin-client solutions and paving the way toward a simplified infrastructure that delivers lower cost of ownership, better usability, and less complexity. Above all, firms need to make sure the laboratory information management system it selects is the best fit for the organization.

Ron Kasner serves as the vice-president of corporate development for LabVantage Solutions, where he is responsible for directing LabVantage's long-term product strategies, global marketing initiatives, and business development opportunities. LabVantage Solutions, Inc., 1160 US Highway 22 East, Bridgewater, NJ 08807, tel. 908.333.0103, fax 908-842-0338,
.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here